Cencora (COR) 10-K Summary — Year Ended Sep 30, 2024
Cencora is a global pharmaceutical sourcing and distribution services company. The filing reports revenue growth over the past year and highlights strong operating cash flow, while noting risks and a multi-year opioid litigation payment obligation.
Key takeaway
Year ended Sep 30, 2024 · FY2025 10-K
Cencora is a global pharmaceutical sourcing and distribution services company. The filing reports revenue growth over the past year and highlights strong operating cash flow, while noting risks and a multi-year opioid litigation payment obligation.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$294B
Revenue reported for the fiscal year.
Operating income
$2.2B
Income from operations reported for the year.
Net income
$1.5B
Net income reported for the year.
Operating cash flow
$3.5B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2021 | $214B | n/a |
| Sep 30, 2022 | $238.6B | +11.5% |
| Sep 30, 2023 | $262.2B | +9.9% |
| Sep 30, 2024 | $294B | +12.1% |
Business overview
Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, serving healthcare providers and pharmaceutical manufacturers. It distributes brand-name, specialty, and generic pharmaceuticals, over-the-counter products, and home healthcare supplies, and offers related services such as data analytics, consulting, logistics, and pharmacy automation.
Financial performance
Revenue increased compared to the prior year, continuing a multi-year growth trend. Operating income and net income were reported at levels consistent with the company's scale. Operating cash flow was strong, providing significant liquidity.
Material risks
The filing identifies risk factors including cybersecurity and market risks, and contains a cautionary note regarding forward-looking statements and their inherent uncertainties. Specific risk details are not elaborated in the supplied context.
Liquidity and capital
The company relies on cash from operations, credit facilities, and supplier terms to fund working capital, debt repayment, dividends, share repurchases, and acquisitions. Management expects future cash flows to be sufficient to meet ongoing obligations, including opioid litigation payments.
What to watch
Monitor the company's progress on opioid litigation payments and any related cash flow impacts.